Eocene opened lower at $2.39, compared with its previous close of $2.48. In the last trading session, the stock traded between $2.27 and $2.51. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Eocene is now worth
$ 0.06
Resulting in a loss of
$ 99.94 (99.94%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.00 (-0.16%)
Day High
$2.51
Day Low
$2.27
Day Open
$2.39
Prev Close
$2.48
Volume
3,188
1W Return
-10.13%
1M Return
-26.75%
3M Return
-44.98%
6M Return
-46.75%
1Y Return
-74.21%
Market Cap ($ Mn)
3
PE Ratio
-
PB Ratio
0.25
PEG Ratio
-
ROE
-58.16%
ROCE
-63.32%
EPS (TTM)
$-2.72
1 Week
-10.13%
1 Month
-26.75%
3 Months
-44.98%
6 Months
-46.75%
9 Months
-53.72%
Colospan completes feasibility study for colon tissue assessment platform
Colospan Ltd completed a feasibility study for its second technology platform, an intraoperative colon tissue assessment tool. Enrolling 32 patients in Israel, the study achieved 100% measurement success with no technical failures. This validates the clinical foundation for the device, which complements the CG-100 bypass device and supports Galmed's diversification in GI oncology medtech.
2mo agoGalmed Pharma: Aramchol-Xtandi combo triples prostate cancer cell death
Galmed Pharmaceuticals disclosed pre-clinical findings where Aramchol plus enzalutamide caused 3-4x more cell death than enzalutamide alone in VCaP prostate cancer lines. Enzalutamide (Xtandi) sales fell from $8 billion in 2024 to $6 billion in 2025 ahead of 2026-2027 patent expiries in Europe and the US.
2mo agoGalmed Pharma Aramchol ODF boosts CNS exposure 300%
Galmed Pharmaceuticals reported that its new Aramchol ODF formulation achieves ~150% higher systemic bioavailability and ~300% greater CNS exposure than standard oral doses. The rapid-dissolving film addresses dysphagia in up to 80% of Parkinson's patients, enhancing adherence. Galmed views this CNS-optimized approach as a differentiated strategy for potential out-licensing.
3mo agoGalmed develops heart-targeted Aramchol formulation
Galmed Pharmaceuticals Ltd. and Barcode Nanotech have developed a proprietary lipid nanoparticles formulation of Aramchol designed to penetrate heart tissue. This new formulation redirects biodistribution away from the liver to the heart muscle, potentially offering a disease-modifying therapy for cardiac fibrosis.
3mo agoGalmed Pharmaceuticals receives US patent allowance for fibrosis treatment
Galmed Pharmaceuticals has been granted a Notice of Allowance for a US patent focused on the treatment and inhibition of fibrosis. The patent, application number 17863472, protects the company's proprietary methods and compositions.
4mo agoGalmed closes Colospan acquisition with $800K cash increase
Galmed Pharmaceuticals closed the acquisition of Colospan, increasing the cash payment by $800K and replacing a $2M share issuance with a $2M performance-based earnout starting in Q3 2027. The deal includes the CG-100 device, which has shown strong clinical data, and aims to establish a unified GI platform. Galmed's CEO cited a cash balance of $15.6 million as of March 31, 2026, enabling the revised financial structure.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Eocene is now worth
$ 0.06
Resulting in a loss of
$ 99.94 (99.94%)
Note: Past profits do not guarantee future returns.
